1-eicosapentaenoylglycerol clinical trials
How each study uses 1-eicosapentaenoylglycerol is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the 1-eicosapentaenoylglycerol studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- MAG-EPA
- 3
Studies by the year they started
4 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2017 | 2 |
| 2019 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
SCF Pharma (2) · CHU de Quebec-Universite Laval (1) · Samuel Fortin (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test 1-eicosapentaenoylglycerol.
- May 2027Modulation of the Brain Fog Scale by Eicosapentaenoic Acid Monoglycerides (MAG-EPA).Phase 4 · Samuel Fortin
Studies
Open first, then newest update. How each study uses 1-eicosapentaenoylglycerol is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Modulation of the Brain Fog Scale by Eicosapentaenoic Acid Monoglycerides (MAG-EPA).RecruitingPhase 4Samuel FortinNCT06695910Written as Monoglyceride Eicosapentaenoic acid (omega-3)
- Effects of EPA in Men With Biochemical Recurrence or Progression of Prostate Cancer.Active, not recruitingPhase 2CHU de Quebec-Universite LavalNCT03753334Written as MAG-EPA
- Comparative Study of Three Different Formulations of Omega-3 (EPA+DHA)CompletedPhase 4SCF PharmaNCT04159532Written as MAG-EPA/MAG-DHA
- Effect of Omega-3 Index on Cellular Metabolism and Quality of LifeCompletedPhase 4SCF PharmaNCT03159507Written as MAG-EPA
Codes
What other systems call 1-eicosapentaenoylglycerol · ClinicalTrials.gg INT006490
- MeSH (NLM) C5882851-eicosapentaenoylglycerolOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C588285 | 1-eicosapentaenoylglycerol | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.